| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
WAY-638394 does not have a well-defined pharmacological target. It is a laboratory reagent that may be useful for treating bone deficit conditions. The compound is also known as 2-Quinolinecarboxamide, N-[4-(4-morpholinyl)phenyl]-. Its precise mechanism of action has not been extensively characterized.
|
|---|---|
| ln Vitro |
In vitro activity of WAY-638394 has not been extensively characterized. As a laboratory reagent, it is used for research purposes. The compound may have activity related to bone metabolism or bone deficit conditions. However, detailed in vitro activity data are not readily available from publicly accessible sources.
|
| ln Vivo |
In vivo, WAY-638394 may be useful for treating bone deficit conditions. However, detailed in vivo efficacy data are limited in publicly available sources. The compound is primarily a research reagent and has not been developed as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for WAY-638394 would typically involve screening against a panel of targets to identify potential activities related to bone metabolism. The compound could be screened against receptors or enzymes involved in bone formation or resorption. Binding assays using surface plasmon resonance or radioligand binding could be employed to identify molecular targets.
|
| Cell Assay |
In vitro cell-based assays for WAY-638394 would involve culturing bone-related cells (e.g., osteoblasts, osteoclasts) and treating them with the compound to assess effects on cell proliferation, differentiation, or function. Markers of bone formation (e.g., alkaline phosphatase, osteocalcin) or bone resorption (e.g., TRAP) would be measured. Cell viability is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies for WAY-638394 have not been extensively reported. If conducted, such studies might involve animal models of bone deficit conditions, such as ovariectomized mice (osteoporosis model) or bone fracture models. WAY-638394 would be administered, and bone mineral density, bone histomorphometry, and other bone-related parameters would be assessed. No specific data are available.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of WAY-638394 have not been characterized. As a small molecule with a molecular weight of 333.38 and a molecular formula of C20H19N3O2, it is expected to have moderate oral bioavailability. Detailed PK parameters such as half-life, Cmax, and bioavailability are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of WAY-638394 has not been systematically evaluated. As a laboratory reagent and research compound, it is handled with standard laboratory precautions. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| Additional Infomation |
WAY-638394 is a research compound and has not been approved for clinical use. It is a laboratory reagent that may be useful for treating bone deficit conditions. WAY-638394 is also known as 2-Quinolinecarboxamide, N-[4-(4-morpholinyl)phenyl]-. It is used for laboratory research and industrial production. The compound's precise mechanism of action has not been extensively characterized.
|
| Molecular Formula |
C20H19N3O2
|
|---|---|
| Molecular Weight |
333.384
|
| Exact Mass |
333.15
|
| Elemental Analysis |
C, 72.05; H, 5.74; N, 12.60; O, 9.60
|
| CAS # |
190437-83-3
|
| PubChem CID |
2580230
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
444
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1COCCN1C2=CC=C(C=C2)NC(=O)C3=NC4=CC=CC=C4C=C3
|
| InChi Key |
DLPXDCIRVDWTMX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H19N3O2/c24-20(19-10-5-15-3-1-2-4-18(15)22-19)21-16-6-8-17(9-7-16)23-11-13-25-14-12-23/h1-10H,11-14H2,(H,21,24)
|
| Chemical Name |
N-[4-(4-Morpholinyl)phenyl]-2-quinolinecarboxamide
|
| Synonyms |
WAY-638394; WAY 638394; WAY638394;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9996 mL | 14.9979 mL | 29.9958 mL | |
| 5 mM | 0.5999 mL | 2.9996 mL | 5.9992 mL | |
| 10 mM | 0.3000 mL | 1.4998 mL | 2.9996 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
